Docket No.: 0230-0242PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Yukio KATO et al.

Application No.: 10/594,595 Confirmation No.: 5586

Filed: September 28, 2006 Art Unit: 1632

For: THERAPEUTIC AGENTS AND

THERAPEUTIC METHODS FOR TREATING

INJURED TISSUE

Examiner: S. L. Chen

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 June 10, 2011

Sir:

Applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08.

II. COPIES

a. Copies of foreign patent documents, non-patent literature and other information.

b. REFERENCES PREVIOUSLY CITED OR SUBMITTED: Copies of any information not provided can be found in one or more of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Application No. and U.S. Filing Date

Application No.: 10/594,595 Docket No.: 0230-0242PUS1

III. CONCISE EXPLANATION OF THE RELEVANCE

a. NON-ENGLISH LANGUAGE DOCUMENTS: A concise explanation of the relevance of all non-English language patents, publications, or other information listed is as follows: English language translations are attached for Non-Patent Literature documents Kato 2002, Kato 2003 and Azuma. English language translations are attached for WO 03/013588 A1 and JP 2001-089471 A. An English language abstract is attached for JP 2004-501608 T.

b. ENGLISH LANGUAGE SEARCH REPORT OR FOREIGN PATENT OFFICE COMMUNICATION: An English language version of the search report or Foreign Patent Office communication that indicates the degree of relevance is attached.

C. OTHER: The following additional information is provided. JP 2004-501608 T corresponds to WO 01/70174 and WO 02/33094 corresponds to US 2004/0086507.

IV. STATEMENT UNDER 37 C.F.R. § 1.97(e)

The undersigned hereby states that:

a. Each item of information contained in the IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than <u>30</u> days prior to the filing of this IDS. This statement does not relate to English language counterparts not listed in a communication from the foreign patent office. Such English language counterparts are provided to aid the Examiner's consideration of non-English items first cited in the communication from the foreign patent office; or

b. Each item of information contained in the IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than **three months** prior to the filing of this IDS. This statement does not relate to English language counterparts not listed in a communication from the foreign patent office. Such English language counterparts are provided to aid the Examiner's consideration of non-English items first cited in the communication from the foreign patent office; or

Application No.: 10/594,595 No item of information contained in the IDS was cited in a communication from a c. foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. d. Some of the items of information in the IDS were cited in a communication from a foreign patent office. Such items were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. This statement does not relate to English language counterparts not listed in a communication from the foreign patent office. Such English language counterparts are provided to aid the Examiner's consideration of non-English items first cited in the communication from the foreign patent office. As to the remaining items of information, to the knowledge of the person signing the certification after making reasonable inquiry, such remaining items were not known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. ٧. FEES This Information Disclosure Statement is being filed concurrently with the filing a. of a new patent application or Request for Continued Examination. No fee is required. b. This Information Disclosure Statement is being filed within three months of the filing date of an application. No fee is required. This Information Disclosure Statement is being filed before the mailing date of a c. first Action on the merits. No fee is required. If a first Office Action on the merits has issued,

Docket No.: 0230-0242PUS1

please consider this IDS under 37 C.F.R. § 1.97(c) and see the statement under 37 C.F.R. §

1.97(e) above. If no statement has been made, charge our deposit account for the required fee.

Application No.: 10/594,595 Docket No.: 0230-0242PUS1

\boxtimes	d.	This Information Disclosure Statement is being filed before the mailing date of a
Final	Office	Action or before the mailing date of a Notice of Allowance (see 37 C.F.R. §
1.97(c)(1)).		
		No statement. The fee as required by 37 C.F.R. § 1.17(p) is provided.
		or
	\boxtimes	See the above statement. No fee is required.
□ Final	e. Office	This Information Disclosure Statement is being filed <u>after</u> the mailing date of a Action or <u>after</u> the mailing date of a Notice of Allowance (see 37 C.F.R. § 1.97(d)),
see the statement above. The fee as required by 37 C.F.R. § 1.17(p) is provided.		
VI.	PAYN	MENT OF FEES
		The required fee is listed on the attached Fee Transmittal.

If the Examiner has any questions concerning this IDS, please contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the USPTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

Dated: June 10, 2011 Respectfully submitted,

Gerald M. Murphy, Jr.

Registration No.: 28,977

BIRCH, STEWART, KOLASCH & BIRCH, LLP

#47,604

12770 High Bluff Drive

Suite 260

San Diego, California 92130

(858) 792-8855

Attorney for Applicant

Attachments: PTO/SB/08; Documents;

 \boxtimes

No fee is required.

Foreign Patent Office Communication